Category: Patent Litigation

    By James DeGiulio — Pozen Secures Injunction Blocking Par's Generic Treximet Earlier this month, Pozen obtained a preliminary injunction blocking Par Pharmaceutical from marketing a generic version of Pozen's migraine drug Treximet until an infringement suit over the drug is resolved.  The dispute between the parties began in November 2008 when Pozen brought suit in…

By James DeGiulio — Cordis Stent Found to Infringe Boston Scientific Patent Boston Scientific Corp. secured a favorable ruling on summary judgment in its patent infringement suit against Cordis Corp. over one of its drug-eluting stents.  In 2003, Boston Scientific sued Cordis in the U.S. District Court for the District of Delaware for infringement of…

By James DeGiulio — Cephalon's Fentora Patent Found Valid, Infringed by Watson Cephalon enjoyed a needed victory in its patent dispute with Watson over Fentora after one of the patents at issue in the case was upheld and Watson's proposed generic of Fentora was found to infringe that patent.  The dispute between the parties began…

By James DeGiulio — Apotex's Generic Provigil Found Not to Infringe Cephalon Patent Apotex received a favorable ruling on summary judgment in its dispute with Cephalon regarding the narcolepsy drug Provigil after the U.S. District Court for the Eastern District of Pennsylvania determined that Apotex's proposed generic does not infringe one of two Cephalon patents…

By James DeGiulio — Watson Invalidates Cephalon's Fentora Patents Watson Pharmaceuticals won a substantial victory in its lawsuit with Cephalon over Fentora when the generic drugmaker successfully established that two of three asserted patents covering the drug are invalid.  The dispute between the parties began in June 2008, when Cephalon filed suit against Watson in…

By James DeGiulio — Abbott and Elan End TriCor Suit with Ranbaxy After only a few months, Abbott Loaboratories and Elan Pharma International, along with Abbott subsidiary Fournier Laboratories, have dropped their patent suit against Ranbaxy Laboratories over the latter's generic version of the cholesterol drug TriCor.  The dispute between the companies began in June…

By James DeGiulio — Medicis and Q-Med Settle Restylane Dispute with Genzyme Genzyme has agreed to drop its infringement suit with Medicis regarding the cosmetic injection product Restylane in exchange for a lump sum payment from Q-Med.  In October 2010, Genzyme brought suit in the U.S. District Court for the District of Massachusetts against Medicis,…

By James DeGiulio — Abbott Fails to Stay Patent Dispute with Wyeth over Stents Despite pending reexaminations over the patents-in-suit, Abbott Laboratories was unsuccessful in its attempt to stay litigation with Wyeth over patents for drug-coated stents.  On September 22, 2009, Wyeth filed suit against Abbott in the U.S. District Court for the District of…

By James DeGiulio — Jury Awards Abbott $16M in Tarka Patent Suit Against Glenmark Abbott Laboratories has been awarded $16 million in its suit against Glenmark Pharmaceuticals over a generic version of the blood pressure drug, Tarka, after a federal jury found Glenmark liable for infringement.  In October 2007, Glenmark notified Abbott and Sanofi that…

By James DeGiulio — PDL BioPharma Synagis Patent Invalidated MedImmune gained major ground in its infringement and licensing dispute with PDL BioPharma after its last patent on antibodies used in the respiratory drug Synagis was found invalid.  The relationship between the parties began in 1997, when PDL granted MedImmune a license to develop certain types…